about
Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil.Human JCV infections as a bio-anthropological marker of the formation of Brazilian Amazonian populationsJC polyomavirus infection in candidates for kidney transplantation living in the Brazilian Amazon region.HBV Viral Load and Liver Enzyme Levels May Be Associated with the Wild MBL2 AA Genotype.Infectious Agents As Markers of Human Migration toward the Amazon Region of Brazil.GBV-C/HIV-1 coinfection is associated with low HIV-1 viral load and high CD4(+) T lymphocyte count.JC virus/human immunodeficiency virus 1 co-infection in the Brazilian Amazonian region.Prevalence and risk behaviour for human immunodeficiency virus 1 infection in Marajó Island, Northern Brazil.Lack of evidence for human infection with Xenotropic murine leukemia virus-related virus in the Brazilian Amazon basin.Human T-lymphotropic virus 1aA circulation and risk factors for sexually transmitted infections in an Amazon geographic area with lowest human development index (Marajó Island, Northern Brazil).FAS-670A/G single nucleotide polymorphism may be associated with human T lymphotropic virus-1 infection and clinical evolution to TSP/HAM.Family Aggregation of HTLV-1 Infection Associated with FAS -670A/G Polymorphism: A Case Report.No evidence of association between MBL2A/O polymorphisms and Mycobacterium tuberculosis infection in populations from the Brazilian Amazon region.Prevalence of infection by JC and BK polyomaviruses in kidney transplant recipients and patients with chronic renal disease.IFNG +874T/A polymorphism and cytokine plasma levels are associated with susceptibility to Mycobacterium tuberculosis infection and clinical manifestation of tuberculosis.High prevalence of human T-lymphotropic virus 2 (HTLV-2) infection in villages of the Xikrin tribe (Kayapo), Brazilian Amazon regionIsolation of the Arawete and Asurini Indians keeps the tribes free from HTLV infection during 36 years of follow-upInfluence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons
P50
Q33755753-98A4626A-5C99-4AA9-90E1-DCA2E36ECE7AQ34447201-E6466930-0316-4BAD-89F5-C66691AFF36EQ37675210-D1DC7F55-D163-4572-A512-5F8EEE5D96DCQ37734379-F895759E-D976-4C37-BB4B-BF8EA0778AD4Q40039893-0C494D6C-4BC7-44BE-B605-D3B40C0601A3Q40093263-0EDFF304-5954-4F3A-9F44-FC1A0E5BB740Q40644019-09C1A2E1-3B9D-4967-B561-EC5A0318340DQ40652967-CBA4B140-9984-4BBA-91FD-6A19A5DE1BF5Q42202982-B405D4ED-AD0D-45E7-8E7B-C180F2899BF6Q45323638-06F35D6B-5D58-4C1B-BF0A-714C3E0F62B0Q45362789-6E08EECE-9A47-46AC-B502-B86FC0EE596EQ47548076-DCB7511A-AB66-49E9-942B-068F9118E80DQ54290964-39794F2F-23E0-4DFA-BD54-E16ECB5BD3E3Q54382616-F8E12BA1-96D0-4FFA-8CE4-0CF12BE49F83Q54434488-A6253E75-AFAD-4CEA-B4A0-AC45D0A74621Q64279782-A937C1CA-7FE4-4865-90E7-C7DCAE2943A9Q90880276-F1241D96-7F01-4A8E-92FB-F9A0724ACADFQ90945284-4F805A59-C224-46D9-8FF9-70AC566C3E7A
P50
description
investigador
@es
researcher
@en
name
I M V Cayres-Vallinoto
@en
type
label
I M V Cayres-Vallinoto
@en
prefLabel
I M V Cayres-Vallinoto
@en
P31
P496
0000-0003-1408-8384